Shares of United Therapeutics (UTHR) and Liquidia (LQDA) are moving sharply in opposite directions in Friday afternoon trading. Shares of United ...

Although BTIG still believes Liquidia has favorable odds of prevailing against United’s ‘327 patent, the firm reduced the probability of success for Liquidia’s drug, Yutrepia, in treating pulmonary ...

We sifted through the Finviz stock screener to compile a list of the top 10 biotech stocks with an upside potential of over ...

In a report released yesterday, Andreas Argyrides from Oppenheimer maintained a Sell rating on Liquidia Technologies, with a price target of $6.00. The company’s shares closed yesterday at $19.26.

Arquitos Capital Management gained 13.1% in Q2 2025. Learn how they turned market uncertainty into opportunity with Liquidia ...

Liquidia shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 82.

Liquidia Corporation (NASDAQ:LQDA) is one of the best low priced pharma stocks to buy now. On June 24, Liquidia announced the receipt of an additional $50 million from Healthcare Royalty/HCRx. The ...

Because Liquidia made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now.

Liquidia has completed the INSPIRE trial (NCT03399604), or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study ...

Liquidia (NASDAQ:LQDA – Get Free Report) had its target price boosted by equities research analysts at Scotiabank from $36.00 to $37.00 in a report issued on Wednesday,Benzinga reports. The firm ...

Liquidia Co. (NASDAQ:LQDA – Get Free Report) gapped down prior to trading on Wednesday following a dissappointing earnings announcement. The stock had previously closed at $14.74, but opened at ...